Hydroxyurea use while Breastfeeding

Drugs containing Hydroxyurea: Hydrea, Droxia, Mylocel

Hydroxyurea Levels and Effects while Breastfeeding

Summary of Use during Lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.

Drug Levels

Maternal Levels. A mother was taking 500 mg of hydroxyurea orally three times a day. Milk samples taken 2 hours after the last dose of each day on 3 days averaged 6.1 mg/L (range 3.8 to 8.4 mg/L). Using these data, the infant in this case would have received less than 4% of maternal weight-adjusted dosage.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Possible Effects on Lactation

Relevant published information was not found as of the revision date.

References

1. Sylvester RK, Lobell M, Teresi ME et al. Excretion of hydroxyurea into milk. Cancer. 1987;60:2177-8. PMID: 3481556

Hydroxyurea Identification

Substance Name

Hydroxyurea

CAS Registry Number

127-07-1

Drug Class

  • Antineoplastic Agents

Administrative Information

LactMed Record Number

140

Information from the National Library of Medicine's LactMed Database.

Last Revision Date

2013-09-07

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

See Also...

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web2)